Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 4/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326761 | 0.91 | ELANE (0.35) | ELANEGPR119MAPTOGAKDM1A | |
| SCHEMBL21470756 | 0.85 | ESR2 (0.38) | GPR119MAPTGHSRNR1H2SMN1; SMN2 | |
| SCHEMBL31569123 | 0.79 | GPR119 (0.39) | GPR119MAPTUCHL1 | |
| SCHEMBL31569021 | 0.79 | GPR119 (0.39) | GPR119MAPTUCHL1 | |
| SCHEMBL31505358 | 0.78 | GHSR (0.45) | ELANEGHSRNR1H2SMN1; SMN2 | |
| SCHEMBL31505321 | 0.77 | MAP4K4 (0.36) | GHSRNR1H2UCHL1 | |
| SCHEMBL31568944 | 0.76 | ESR2 (0.36) | ELANEMAPTGHSRNR1H2SMN1; SMN2 | |
| SCHEMBL31569084 | 0.76 | POLB (0.44) | GPR119MAPT | |
| SCHEMBL31569147 | 0.76 | POLB (0.44) | GPR119MAPT | |
| SCHEMBL21470478 | 0.76 | HDAC8 (0.38) | ELANEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | ELANE 2775/4885GPR119 329/4885MAPT 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.